Elafibranor
Elafibranor is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor gamma.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | 1 | — | — | 2 |
| Biliary liver cirrhosis | D008105 | K74.3 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Abdominal obesity | D056128 | HP_0001956 | — | 3 | — | — | — | 3 | |
| Alcoholic fatty liver | D005235 | K70.0 | — | 2 | — | — | — | 2 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | — | — | 2 |
| Insulin resistance | D007333 | EFO_0002614 | — | 1 | — | — | — | 1 | |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
| Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
| Dyslipidemias | D050171 | HP_0003119 | 1 | — | — | — | — | 1 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ELAFIBRANOR |
| INN | elafibranor |
| Description | Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 923978-27-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707395 |
| ChEBI ID | — |
| PubChem CID | 9864881 |
| DrugBank | DB05187 |
| UNII ID | 2J3H5C81A5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PPARA
PPARA
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARA
Gene synonyms
NR1C1, PPAR
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor alpha
Protein synonyms
Nuclear receptor subfamily 1 group C member 1, peroxisome proliferative activated receptor, alpha
Uniprot ID
Mouse ortholog
Ppara (19013)
peroxisome proliferator-activated receptor alpha (P23204)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 679 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more